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1. Indroduction 
The intact gastrointestinal mucosa can be kept as good equilibrium between the aggressive 
and defensive factors. These factors have not been fully discovered, however the main 
aggressive factors are well defined. Gastritis is defined as a pathomorphological appearance 
of inflammation in the gastric mucosa. Gastritis may be caused by different factors such as 
Helicobacter pylori (H. pylori), bacterial overgrowth in a hypochlorohydric stomach, 
autoimmune mechanisms or chemical agents such as short and long-term nonsteroidal anti-
inflammatory drug therapy.  
The possible physiological, pathological and pharmacological role(s) of afferent nerves has 
(have) not been analyzed just recent studies search on its most important role(s) in GI 
physiology, pathology and pharmacology. Our attention has been focused on capsaicin-
sensitive afferent nerves during the last decades. 
The possible roles of the capsaicin-sensitive afferent nerves have been approached to 
gastrointestinal tract from the years of 1980 by our work-team in animal experiments, in 
healthy human subjects with histological intact and in patients with different disorders 
(Mózsik et al., 1997, 2001, 2005a, 2007). Capsaicin (given it in small doses) protected the 
gastrointestinal mucosal damage induced by different necrotizing agents (such as physical, 
chemical, drugs, etc.) in animal experiments and in human healthy subjects, in patients with 
different gastrointestinal disorders (Mózsik et al., 1997, 2005a, 2007, 2009). The functional 
state of some part of afferent nerves (capsaicin-sensitive afferent nerves) can be modified by 
application of capsaicin by a dose-dependent process (capsaicin, given in small doses 
stimulates, meanwhile given in higher dose produces reversible and irreversible inhibition 
or impairment) (Szolcsányi et al., 1984a; Mózsik et al., 2001).  
1.1 Aims of observations 
The aims of our observations were: 
To study the distribution of capsaicin receptor (TRVP1), calcitonin gene-related peptide 
(CGRP) and substance P (SP) in  the human gastric mucosa in histologically intact with 
functional dyspepsia, chronic gastritis (diagnosed histologically); 
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To evaluate the possible role of capsaicin-sensitive afferent nerves in the development of 
gastritis produced by H. pylori; 
To analyse the role of capsaicin afferent nerves (e.g.immunhistochemical distribution of 
TRVP1, CGRP, SP) in the the gastric mucosa of the same patients with chronic gastritis 
produced by H. pylori before and after eradication treatment;  
To approach the possible gastric mucosal defensive mechanisms of capsaicin-sensitive 
afferent nerves (immunhistochemical distribution of TRVP1, CGRP, SP) in the development 
of gastritis and its treatment;  
To demonstrate a new pathway (namely the possible productions of new chemical 
compounds acting on the capsaicin-sensitive afferent nerves) to introduce (as one of the 
possibilities) in the treatment of chronic gastritis. 
1.2 Patients and methods 
The patients with symptoms suffering from functional complaints (n=40), chronic gastritis 
with H. pylori negative (gastric discomfort sensation, nausea, loss of appetite, vomiting) 
(n=30) and H. pylori positive (n=39) infection. The age of patients was between 39 to 68 
years, and these patients were near to be equal to males and females. 
Gastric biopsies were collected from the hyperaemic areas of the corpus and antrum of the 
stomach by oesophago-gastrosco-bulboscopy. The H. pylori infection was detected using the 14C 
urea breath test (14C UBT), the rapid urease test, and specific histological examinations. The 
gastric tissue samples were classified into the different groups of chronic gastritis to the updated 
Sydney system by an independent histopathologist (Dömötör et al., 2007, Lakner et al., 2010). 
The immunhistochemical studies were carried out on formalin fixed, paraffin embedded 
tissue samples using anti-TRVP1 receptor, anti-SP and anti-CGRP antibodies.  
18 patients with H. pylori positive chronic gastritis went over the same physical, laboratory, 
ultrasonographic, endoscopic and histological examinations (mentioned above) before and 
after eradication treatment.  
1.3 Results 
Distribution of TRVP1 positive (20%) and negative (80%), CRGP positive (30%) and negative 
(70%), SP weak (75) and strong (25%) in gastric mucosa of healthy human subjects. TRVP1 
positive 82%, and negative 18%, CGRP positive 80% and negative 20%, SP weak 85% and 
strong 15% in patients with H. pylori positive chronic gastritis. TRVP1 positive 70% and 
negative 30%, CGRP positive 63% and negative 37%, SP weak 59% and strong 28% in 
patients with H. pylori negative chronic gastritis. 
The eradication treatment for H. pylori infection was successful (in 16 from 18, 89%) and 
complaints (epigastrial pain, heart burn, abdominal expansion) also decreased. 
Histologically healthy gastric mucosa could be detected only in 22% (4 from 18) and 
appearance of gastric mucosa (just in moderate histological picture) was obtained. 
TRVP1 positive 89% and negative 11%, CGRP positive 100%, SP positive 6% and negative 
94% in patients with H. pylori positive gastritis, before eradication treatment. TRVP1 positive 
72% and negative 18%, CGRP positive 100%, SP negative 100% in patients with H. pylori 
positive chronic gastritis after classical eradication treatment. 
1.4 Main conclusions 
H. pylori does not represent an exclusive factor for the development of chronic gastritis in 
patients. The many other compounds (physical, chemical agents) are able also to produce 
chronic gastritis in patients. 
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The expression of TRVP1 and increased CGRP participated in the development of chronic 
gastritis (without and with H. pylori infection), meanwhile the SP probably does not 
participate in this process. These results clearly indicate that the histological picture of 
chronic gastritis is independent from the presence of commonly emphasized role of H. pylori 
infection in patients, and much more complicated series of mechanisms are  present in  the 
development of human chronic gastritis (as we now suggest those at this time). 
The classical eradication human therapy does not modify the immunhistological 
distribution of TRVP1, CGRP and SP in the human gastric mucosa with H. pylori infection. 
Many animal and human observations indicated that the stimulation of capsaicin-sensitive 
afferent nerves by application by small doses of capsaicin (or other compounds) produced 
defensive effects against the different physical, chemical, bacteriological, immunological 
agents. 
The capsaicin-sensitive afferentation (s) has (have) a permanent defensive role(s) against 
gastric mucosal damage by different noxious agents, in the human gastric mucosa. The 
innovative pharmacological research may offer a new pathway to prevent the gastric 
mucosa induced by different agents (including the H. pylori infection).  
2. Introduction 
The principle role of efferent vagal nerves has been emphasized in the development of 
gastrointestinal mucosal damage and prevention, as well as in medical treatment involving 
anticholinergic agents, histamine H2 receptor inhibitors, proton pump inhibitors during the 
last century. From the initial observation of capsaicin desensitation phenomenon, a long-
lasting chemoanalgesia and impairment of thermoregulation in the 1970s, chain of new 
discoveries led to the discovery of the capsaicin receptor, a type of C-polymodal nociceptors 
(Szolcsányi, 2004b). The effects of capsaicin depend on the applied doses and duration of 
exposure (Mózsik et al., 2001; Szolcsányi, 2004a). These different effects of capsaicin are: (1) 
excitation; (2) sensory-blocking effect; (3) long-term selective neurotoxic impairment and (4) 
irreversible cell destruction. 
Neurogenic inflammation is mediated by these C-afferents, which are supplied by the 
putative capsaicin receptor. These afferents are called capsaicin-sensitive chemoreceptive 
afferents. They opened new avenues of local peptidegic regulation in peripheral tissues. It 
has been suggested that, in contrast to classical axon theory, capsaicin-sensitive sensory 
system has a dual sensory-afferent function, whereby initiation of afferent signals and 
neuropeptide release are coupled at the same nerve endings. Furthermore, for instance in 
the skin at threshold stimuli which do not evoke sensation already maximum efferent 
response as enhanced microcirculation is elicited. Recently, the capsaicin receptor has been 
cloned and named as transient receptor potential vanilloid-1 (TRVP1) (Caterina et al., 1997). 
TRPV1 was detected in the area postrema and in the nucleus tractus solitarii where the 
afferent fibres of the vagal nerve come to an end. Studies with capsaicin receptor led to 
discovery of the first temperature-gated ion channel gated by noxious heat, protons, 
vanilloids and endogenous ligands as anadamide, N-oleodopamine and lypoxygenase 
products. Another recent achievement was the discovery of a novel neurohormonal 
regulatory mechanisms mediated by somatostatin. Somatostatin released from the TRVP1-
expressing nerve endings reaches the circulation and elicits anti-inflammatory and analgetic 
sensory functions (Szolcsányi, 2004; Helyes et al., 2004). 
The vagal nerve contains also only 10% efferent and 90% of afferent nerve fibres, and 9% of 
these afferent fibres are the capsaicin-sensitive afferent nerves (Gabellla & Pease, 1973; 
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Grijalva & Novin, 1990). Thus, the amount of the efferent nerves and the capsaicin-sensitive 
afferent nerves are roughly the same amount in the vagal nerve. 
The possible role of afferent vagal nerve was studied in the last decades both in 
development of gastrointestinal mucosal damage and protection (Mózsik et al., 1997; 2004a; 
Holzer, 1999; Abdel-Salam et al., 1999). Recently, the gastroprotective effect of capsaicin 
against chemical agents (ethanol, indomethacin) has been proven in human healthy subjects 
(Mózsik et al., 2004b, 2005). The beneficial effect of capsaicin has also been shown in patients 
with functional gastrointestinal disorders (Bartolotti et al. 2002; Bhat & Bielefeldt, 2006). 
The integrity of gastric mucosa is an equilibrium state between aggressive and defensive 
factors. The loss of this balance leads to the development of most gastric disorders, like 
gastric mucosal ulceration and most likely chronic gastritis.  
One of the aggressive factors is H. pylori infection, which is a wide spread bacteria, one of 
the commonest pathogen bacillus in humans (Hocker & Hohenberger, 2003). At least half of 
the world’s population could be infected with this organism (Logan & Walker, 2001). H. 
pylori - as a causative factor - increases the risk for development of human gastrointestinal 
disorders such as acute gastritis, chronic gastritis, gastric ulcer, gastric mucosa-associated 
lymphoid tissue (MALT) lymphoma, gastric adenocarcinoma, duodenal ulcer and it may be 
implicated in iron deficiency anemia and also in extra-gastrointestinal disorders (ischemic 
heart disease, ischemic cerebrovascular disease, atherosclerosis etc) (Parsonet, 1995; Peng et 
al., 1998; Pakodi et al., 2003; Mitani et al, 2004; Janulaityte-Gunther et al., 2005; Salih et al., 
2005;   Zhang et al., 2005a). The eradication of this organism has generally been associated 
with histological improvement of gastritis (Salih et al., 2005).  
On the other hand, one of the defensive mechanisms is the capsaicin-sensitive afferentation. 
During administration of small doses of capsaicin (from ng/kg to μg/kg body weight) 
neurotransmitters such as substance-P (SP), calcitonin-gene related peptide (CGRP) and 
somatostatin (SS) are released from this nerve endings (Holzer, 1998, 1999; Szolcsányi, 2004). 
These mediators can increase mucosal blood flow by vasodilatation (Holzer et al., 1991), can 
activate mast cells and immunocells in the mucosa (Stead, 1992), and somatostatin can elicit 
systemic anti-inflammatory and analgetic “sensory functions”. The immunodistribution of 
neuropeptides (SP, VIP, NPY, SOM, GAL, and TH) released from the sensory neurons and 
their neuroimmune function are known in H. pylori positive gastritis, but not have been 
examined in gastritis without H. pylori infection (Sipos et al., 2006). 
The presence of this receptor and released neurotransmitters could be studied in the 
development of human gastrointestinal disorders including gastritis, peptic ulcer, polyp 
without and with dysplasia, tumour and inflammatory bowel diseases by immunhistological 
method (Kihara et al., 2003; Zhang et al., 2005b; Dömötör et al., 2005; Mózsik et al., 2007). In 
our further research significant changes were observed in the immunhistological distribution 
of TRPV1, CGRP and SP in patients with chronic H. pylori positive gastritis and in histological 
healthy subjects but no change could be detected between the patients suffered from chronic 
gastritis without or with H. pylori infection (Dömötör et al., 2006). The effect of omeprazole and 
omeprazole-like compounds could also be demonstrated in the gastric mucosa of rats by the 
changes of the TRPV1, CGRP and SP immunodistribution and by the reduction of number and 
severity of gastric mucosal lesions (Mózsik et al., 2005b).  
3. Materials and methods  
The symptoms of patients suffering from chronic gastritis with or without H. pylori 
infection (21 H. pylori positive, 30 H. pylori negative) were nonspecific (gastric discomfort 
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sensation, nausea, loss of appetite, vomiting). The patients underwent physical, laboratory, 
ultrasonographic, endoscopic and histological examinations at the First Department of 
Medicine, Medical and Health Centre, University of Pécs, Hungary (Table 1).  
Twenty people with functional dyspepsia (all of them underwent the aforementioned 
medical, laboratory, iconographic, and histological examinations and all of these 
examinations indicated absolutely negative results) were taken as healthy controls. The age 
of patients was 39 to 68 years; there were 22 males and 29 females with chronic gastritis and 
10 males and 10 females in the functional dyspepsia group (Table 1).  
 
 
Patients: 127 patients,  age: 21 – 84 years (68 males, 59 females) 
Preliminary study by Dömötör et al, 2005
Study 1:  51 patients with chronic gastritis
age: 39 – 68 years (22 males, 29 females)
21 H. pylori  positive,  30 H. pylori negative
20 persons with functional dyspepsia (controls)
age: 41 – 67 years (mean: 52,1 years) (10 males, 10 females)
Study 2: 18 patients with H. pylori positive chronic gastritis (6 males, 12 females)
age: 39 – 68 years (mean: 56.4 years)
20 with functional dyspepsia (controls)
age: 41 – 67 years (mean: 52,1 years) (10 males, 10 females)
 
Table 1. Study design. The immunhistological studies for capsaicin-sensitive sensory nerves 
were carried out on biopsy specimens of gastric mucosa obtained from patients. 
Eighteen patients with H. pylori positive chronic gastritis went over physical, laboratory, 
ultrasonographic, endoscopic and histological examinations at the Department of Medicine 
and Gastroenterology, Markusovszky Teaching Hospital, Szombathely (Hungary). The age 
of patients (6 males, 12 females) was 39 to 68 years (mean=56,4 yrs). The symptoms of the 
patients were measured with the same questionnaire. These patient received eradication 
therapy involving a seven days treatment with double dose proton-pump inhibitor (PPI; 
pantoprazole 2x40 mg/ day), amoxycillin (1000 mg twice daily) and clarithromycin (500 mg 
twice daily) according to the actual European guidelines (Malfertheiner et al., 2007). After 
the first week, the patients medicated normal dose of PPI for another week (Table 1). Six 
weeks after eradication therapy these patients underwent second gastroscopy with gastric 
biopsy. 
Gastric biopsies were collected from hyperaemic areas of the corpus and antrum of the 
stomach by gastroscopy. H. pylori infection was detected using the 14C UBT, the rapid 
urease test and specific histological examinations (Warthin-Starry silver staining). Gastric 
tissue samples were analyzed at the Department of Pathology and classified into different 
groups of chronic gastritis according to the updated Sydney system (Prince, 1991). The biop-
sies showed moderate and severe activity of inflammation. Gastric biopsies of patients with 
chronic gastritis and histologically healthy people were classified into groups by an 
independent pathologist. 
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Immunhistological studies were carried out on formalin-fixed, paraffin-embedded tissue 
samples using the peroxidase-labelled polymer method (Lab Vision Corp., USA). SP was 
detected by the NC1/34HL rat monoclonal antibody and TRPV1 receptor and CGRP were 
labelled using polyclonal rabbit antibody (all from Abcam Ltd., Cambridge, UK) (Table 2). 
 
 
Table 2. Antibodies used as primary. 
Immunhistochemical analysis was assessed by light microscopy (Olympus). TRPV1 and CGRP 
were detected as positive or negative, while the immunhistochemical distribution of SP was 
characterized using the "SP index." This index was calculated by counting immunopositive 
spots in at least five high-magnification fields. For fields without immunostaining, the score 
was 0; for fields containing only one positive spot, the score was 1; and for fields with two or 
more stained elements, the score was 2. The total score in one specimen was divided by the 
number of scanned fields to obtain the SP index. Based on these results, biopsies were classed 
into three categories: weak, medium, and strong (Table 3). 
 
SP evaluation SP index
Weak <0.5
Medium ≥ 0.5 but < 1
Strong ≥ 1
 
Table 3. Semiquantitative quantitation of immunhistochemical SP staining in gastric mucosa 
of healthy subjects and patients with chronic gastitis 
Observations were carried out according to Good Clinical Practice (GCP). Human 
examinations were carried out from 1997 to 2010 and were permitted by the Regional 
Ethical Committee of University of Pécs, Hungary. Written informed consent was obtained 
from all participants. 
TRPV1 and CGRP were statistically evaluated by chi-square probe, while SP results were 
semi-quantitatively evaluated by Mann-Whitney's U test. The results were taken to be 
significant at P values of < 0.05. 
4. Results 
Results are presented as the typical pictures of the immunomorphological appearance of the 
studied receptor and mediators in the gastric mucosa in healthy human subjects and in 
patients with chronic gastritis with or without H. pylori infection (Figs. 1-4). 
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The immunhistochemical results are summarized in Table 4. showing the SP scores (mean ± 
SE) in healthy persons and in patients with H. pylori positive and negative chronic gastritis. 
In TRPVl-positive cases of chronic gastritis with or without H. pylori infection and in healthy 
subjects, immunostaining was detected as fine granular cytoplasmic immunosigns in 
epithelial cells in the gastric mucosa (Fig. 2). TRPVl-positive cases of chronic gastritis were 
significantly more frequent (p<0.01) than in controls, while no significant difference was 
detected in immunomorphology of TRPV1 between patients with H. pylori  negative and 
those with H. pylori positive chronic gastritis. 
 
TRPV1
TRPV1
CGRP
SP  
 
Fig. 1. Immunhistochemical distribution of TRPV1, CGRP and SP in mucosa of the stomach. 
Arrows show the immunosigns in the epithelial layer of the gastric mucosa (original 
magnification: 100x). 
 
 
A B C
 
 
Fig. 2. Immunodistribution of TRPV1 in the gastric mucosa of a healthy subject (A) and of 
patient with H. pylori negative (B) and H. pylori positive (C) chronic gastritis. Arrows show 
the immunosigns in the epithelial layer of the gastric mucosa (original magnification: 100x). 
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The characteristic immunodistribution of CGRP was as a fine granular cytoplasmatic 
positivity in epithelial cells in the gastric mucosa of patients with chronic gastritis with or 
without H. pylori infection and in healthy persons (Fig. 3). Regarding the immunhistological 
distribution of CGRP, significant differences were observed between healthy controls and H. 
pylori negative chronic gastritis (p<0.01) and no significant difference was found between the 
two types (H. pylori negative and positive) of chronic gastritis. Although the number of the 
positive tissue samples increased in H. pylori positive gastritis, it did not reach a significantly 
different level compared to healthy controls. 
Before H. pylori eradication, the symptoms of the patients with H. pylori positive chronic 
gastritis were unspecific, epigastrial pain (14/18; 77%), heart burn (13/18; 72%), 
nausea/vomiting (9/18; 50%) abdominal expansion (9/18; 50%), constipation (6/18; 38%). 
The gastric biopsies of patients with H. pylori positive chronic gastritis before eradication 
indicated moderate and severe activity of inflammation during the regular/common 
histopathological examinations. The H. pylori eradication therapy was successful in 16 from 
18 patients (89%) (Figs. 5 and 6). The symptoms were moderated in seven patients (7/18; 
39%) and 11 patients (11/18; 61%) had no complaints after eradication treatment. 
The immunomorphology of SP was detected as small granular spot-like signals along the 
mucosal blood vessels in gastric mucosa of healthy subjects and of patients with chronic 
gastritis with or without the presence of H. pylori infection (Fig. 4). No significant difference 
was observed in the number of low and high SP scores between healthy subjects and 
patients with chronic gastritis, while medium SP immunhistological samples appeared in H. 
pylori negative and positive chronic gastritis. 
The gastroscopy with gastric biopsy was carried out in all patients after H. pylori eradication. 
Histologically healthy gastric mucosa could be detected only in 4 (4/18; 22 %) of the control 
biopsies and in 14 (14/18; 78%) patients the appearance of chronic gastritis (just in moderate 
histological picture).  
 
A B C
 
 
 
Fig. 3. Immunodistribution of CGRP in gastric mucosa of a healthy subject (A), of patient 
with H. pylori negative (B) and H. pylori positive (C) chronic gastritis. Arrows show the 
immunosigns in the epithelial layer of the gastric mucosa (original magnification: 100x).  
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A B C
 
 
 
 
Fig. 4. Immunodistribution of SP in gastric mucosa of a healthy subject (A) and of patient 
with H. pylori negative (B) H. pylori positive (C) chronic gastritis (original magnification: 
100x). 
 
 
 
 
TRVP1 CGRP SP
+ – + – – Weak Medium Strong  
Healthy (n=20) 20% 80% 30% 70% 0 75% 0 25%
H. pylori positive (n=21) 82% 18% 80% 20% 0 85% 0 15%
H. pylori negative (n=30) 70% 30% 73% 27% 0 70% 0 30%
H. pylori positive
before eradication (n=18) 89% 11% 100% 0 94% 0 6% 0
H. pylori positive
after eradication (n=18) 72% 18% 100% 0 100% 0 0 0
 
 
 
 
Table 4. Result of immunhistochemistry examinations for TRVP1, CGRP and SP in gastric 
mucosa of healthy subjects (n=40), patients with H. pylori negative chronic gastritis (n=30) 
and H. pylori positive chronic gastritis (n=18) before and after eradication therapy.  
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Fig. 5. The efficacy of the traditional H. pylori eradication treatment in patients with chronic 
gastritis (n=18) measured by urea breath test.  
The TRPV1 was positive in 20% (5/20) in the healthy subjects, that value was 89 % (16/18; 
p< 0.001) before and 72% (13/18; p< 0.03) after eradication therapy in patients with chronic 
H. pylori positive patients. 
Immunhistochemistry of CGRP was positive in 100% (18/18; p<0.001) of patients before and 
after eradication (18/18; p< 0.001). The SP immunostaing was positive in 25% of control 
persons (20/20), and in 5.5 % (1/18; p> 0.05) before and in 0% (0/18; p>0.05) after 
eradication. The results of the immunhistological examinations are characterized by the 
typical histological pictures of the TRPV1 receptor and the mediators (CGRP and SP) and 
are summarized in Tables 5 and 6. 
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Fig. 6. Presence of histological inflammation in gastric mucosa of patients with chronic 
gastritis after classical H. pylori eradication therapy treatment (n=18). 
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TRVP1 Healthy subjects vs.
vs.
vs. 
H.p. - (+)
H.p. + 
H.p. + 
↑
↑
↑
p<0.0001
p<0.0001
p<0.0001
before eradication
after eradication
CGRP Healthy subjects vs.
vs.
vs.
H.p. - (+)
H.p. + 
H.p. + 
↑
↑
↑
p<0.0001
p<0.0001
p<0.0001
before eradication
after eradication
SP Weak (strong) vs.
vs.
vs. 
H.p. - (+)
H.p. + 
H.p. + 
↑
↑
p>0.005
p<0.0001
p<0.0001
before eradication
after eradication
p values were calculated between the identical results obtained in healthy subjects (n=40), in patients with H. pylori negative  
(n=30) and H. pylori positive chronic gastritis before  (n=18) and after  (n=18) eradication therapy.
↑ means increase.
 
Table 5. Summary of differences in result obtained in immunhistochemistry examinations 
for TRVP1, cGRP and SP in gastric mucosa of healthy subjects (n=40), patients with H. pylori 
negative chronic gastritis (n=30) and H. pylori positive chronic gastritis (n=18) before and 
after eradication therapy.  
5. Discussion 
The possible role(s) of the capsaicin-sensitive afferent vagal nerve has been studied by our 
work-team since the l980s under physiological and different pathological conditions in 
animal experiments (Mózsik et al, 1997, 2001, 2004b; Abdel Salam et al., 1999), healthy 
subjects (Mózsik et al., 2004b, 2005a) and in patients with different gastrointestinal disorders 
(Dömötör et al., 2005, Mózsik et al., 2006, 2007). 
The distribution of TRVP1, CGRP significantly increased in H. pylori positive chronic 
gastritis (in comparison with their distribution in gastric mucosa of healthy subjects), which 
data suggests that the TRPV1 and CGRP are involved in the development of human chronic 
gastritis (Tables 6 and 7). However, no significant changes were obtained before vs. after 
classical eradication treatment in patients with H. pylori positive chronic gastritis (Table 8). 
The SP decreased in patients with H. pylori chronic gastritis and its value unchanged before 
and after eradication treatment. 
Histologically healthy gastric mucosa could be detected only 4 (4/18; 22%) H. pylori positive 
patients chronic gastritis at 6 weeks after classical eradication treatment. It was interesting to 
note, that the distribution of gastric mucosal TRPV1, CGRP and SP did not change in the H. 
pylori positive gastritis before and after classical eradication treatment. 
How can we explain these unchanged immunodistribution in the gastric mucosa of H. pylori 
positive gastric chronic gastritis before and after eradication treatment? 
We have to start from basic observed facts: 1. TRPV1, CGRP and SP can be 
immunhistologically detected in the rat and human gastric mucosa under healthy and 
different pathological circumstances;  2. the changes in expression of TRPV1,  CGRP and SP 
are consequence of activation in the capsaicin-sensitive afferent nerves;  3. the H. pylori 
positivity was proven in all patients with chronic gastritis;  4. the eradication of H. pylori was 
successfully carried out, that associated with significant decrease of patients’ complaints;  5. 
the gastric mucosa became to be negative (intact gastric mucosa) in 25%, and 75% of patients 
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indicate moderate histological signs of gastritis after eradication treatment; 6. independently 
from that the exact proof, the chronic gastritis is in association with H. pylori positivity, the 
histological picture of gastric mucosa indicates only a moderate remission. 
 
TRVP1 positive TRVP1 negative
Healthy subjects (n=20) 20% 80%
H. pylori neg/pos gastritis
(n=51)
↑
(p<0.001)
↓
(p<0.001)
H. pylori pos gastritis (n=18)
Before eradication ↑
(p<0.001)
↓
(p<0.001)
After eradication ↑
(p<0.001)
↓
(p<0.001)
↑ means increase. ↓ means decrease.     NS means no significant difference.    pos means postive. neg means negative. 
NS NS
 
Table 6. Summary of result obtained in immunhistochemistry examinations for TRVP1 in 
gastric mucosa of healthy subjects and patients with H. pylori negative chronic gastritis 
(n=30) and H. pylori positive chronic gastritis before and after eradication therapy (n=18). 
 
CGRP positive CGPR negative
Healthy subjects (n=20) 30% 70%
H. pylori neg/pos gastritis
(n=51)
↑
(p<0.001)
↓
(p<0.001)
H. pylori pos gastritis (n=18)
Before eradication ↑
(p<0.001)
↓
(p<0.001)
After eradication ↑
(p<0.001)
↓
(p<0.001)
↑ means increase. ↓ means decrease.     NS means no significant difference.    pos means postive. neg means negative. 
NS NS
 
Table 7. Summary of result obtained in immunhistochemistry examinations for CGRP in 
gastric mucosa of healthy subjects and patients with H. pylori negative chronic gastritis 
(n=30) and H. pylori positive chronic gastritis before and after eradication therapy (n=18). 
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The TRVP1, CGRP expressions increased significantly in the gastric mucosa with H. pylori 
infection (in comparison with the immunodistribution of TRVP1 and CGRP obtained in the 
gastric mucosa with healthy subjects, and no significant changes were obtained in the 
distribution of SP. 
In the second series of human observation, it was an unexpected result, that the distribution 
of TRVP1, CGRP and SP remained unchanged after the classical eradication treatment in 
patients, although the urea breath test showed high successful rate in bacterial eradication. 
The gastric mucosa did not become to be histologically negative after the eradication 
treatment. Interestingly the ratio between the TRVP1, CGRP positivity vs. negative 
remained the similar before and after eradication. 
To understand the changes in histochemical distribution in the gastric mucosa, we 
performed acute animal experiment, when the rat gastric mucosa was exposed to 
endogenous (HCl) and exogenous (indomethacin) noxious agents. In these experiments 
presence of positive immunodistribution of TRPV1, CGRP and SP decreased acutely, that 
could be abolished by omeprazole (or omeprazole-like compounds) treatment (at 4 hour) 
(Mózsik et al., 2005b) (Figs. 7-10). 
 
 
 
 
 
SP negative SP positive
weak medium strong
Healthy subjects (n=20) 0% 70% 5% 25%
H. pylori pos gastritis (n=21) 0% 85% 5% 15%
H. pylori neg gastritis (n=30) 0% 70% 0 30%
H. pylori pos gastritis (n=18)
Before eradication 94% 0 6% 0
After eradication 100% 0 0% 0
↑ means increase. ↓ means decrease. pos means postive. neg means negative. 
100%
100%
 
 
 
 
 
 
Table 8. Summary of result obtained in immunhistochemistry examinations for SP in gastric 
mucosa of healthy subjects and patients with H. pylori negative chronic gastritis (n=30) and 
H. pylori positive chronic gastritis before and after eradication therapy (n=18). 
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A B C
 
 
Fig. 7. Immunostaining for TVRP1 in rat gastric mucosa. Weak (A), medium (B) and strong 
(C) expression of TRVP1 by glandular cells. The weak antigen expression corresponds with 
immunostaining of some glands in the basal layer. In biopsies with medium expression, 
positive glands are found at the most in half of the mucosa, and in cases with strong TRVP1 
positivity, almost all glands are stained (original magnification: 100x). 
 
A B C
 
 
Fig. 8. Immunostaining for CGRP in rat gastric mucosa. Weak (A; only some glandular cells 
are positive in the mucosa), medium (B; fine granular cytoplasmic staining) and strong (C; 
predominantly in the basal zone, larger granular staining is observed with higher intensity) 
CGRP expression (original magnification: 100x). 
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A B
 
 
Fig. 9. Immunostaining for SP in rat gastric mucosa. The weakly stained mucosa (A) is 
almost negative, however, in positive cases; some fine granular immunostaining was 
observed (B), corresponding to perivascular neural elements (original magnification: 100x). 
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and exogenous
agents alone
Agents + compounds
TRPV1
CGRP
SP
TRPV1
CGRP
SP ?
Time period (h)
A
B
 
 
Fig. 10. Schematic presentation of hypothesis for the changes in immunhistochemically 
demonstrated changes of TRPV1 receptor, CGRP and SP in rat gastric mucosa after 
application of endogenous (HCl) and exogenous (indomethacin) chemical agents without 
(A) and with application of omeprazole and omeprazole like compounds (B) during 4-h 
experimental time period. 
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Table 9. Correlation between the drug actions and histochemistry in indomethacin-treated 
rats (n=5-10). 
 
 
 
 
 
 
 
Table 10. Correlation between the drug actions and immunhistochemistry in pylorus-ligated 
rats. 
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In this case the proton pump inhibitor acts at the level of efferent nerves. The classical 
eradication treatment does not link specifically to efferent or afferent nerves of the vagus. 
There is no question that the 6-week time period after eradication therapy does not offer 
enough time for the histologically restoration of gastric mucosa in patients with chronic H. 
pylori positive gastritis. 
Our explanation for the unchanged immunhistochemical distribution of TRPV1, CGP and 
SP of gastric H. pylori positive chronic gastritis before vs. after eradication treatment:  
1. Six-week time period (including the time of eradication) is not enough time for the 
complete healing of chronic gastritis. Because of patients’ complaints decreased (and 
the eradication treatment was mostly successful), however, the changes in 
gastrointestinal mucosal histology (and immunhistology) showed a lower infection, 
successful eradication treatment, traditional and specific immunhistological distribution 
of TVPV1, CGRP and SP differ from each other. 
2. The six-week time period (after eradication) is probably not enough time for complete 
histologically recovery of chronic H. pylori in patients in term of histology and 
immunhistology. 
3. The H. pylori bacteria as etiological factors might represent only one of the factors 
causing chronic gastritis (in term of histology). 
4. The immunhistological distribution of TRVP1, CGRP and SP are independent on the 
chronic gastritis produced by different physical, chemical, bacteriological or 
immunological agents. It’s true, that the gastric mucosa did not become histologically 
intact after eradication treatment. These changes in the histological picture in the gastric 
mucosa (before and after eradication treatment) suggest that the time period (6 weeks) 
was short for healing the chronic gastritis by eradication treatment. That fact is 
confirmed by the repeated histological examinations. Histologically healthy gastric 
mucosa could be studied only in 4 cases of the control biopsies. In 14 cases, the 
appearance of chronic gastritis became just moderated. 
5. It can be suggested, that other permanent factors (stress, drugs) also take also part in the 
development of chronic gastritis which is in accordance with our further observations. The 
immunomorphology of TRVP1, CGRP and SP do not differ in chronic gastritis evoked 
by different factors (H. pylori, drugs, etc). 
6. Low percentage of participants was refractory to the eradication therapy, so the 
persistent H. pylori infection before and after eradication could maintain the same 
immunhistochemical appearance, the same inflammatory answer. 
We demonstrated that the immunodistribution of vanilloid receptor, CGRP and SP 
increased in patients with chronic gastritis, however, no differences were obtained in the 
immunhistochemical distribution of examined parameters in the gastric mucosa with H. 
pylori positive and H. pylori negative patients (Dömötör et al., 2006). Our presented results 
clearly indicate that the immunhistochemical distribution of vanilloid receptor, CGRP and 
SP after classical eradication treatment in patients with H. pylori positive chronic gastritis (by 
other words the capsaicin-sensitive afferent nerves) are independent from the eradication 
treatment. 
The knowledge, that the capsaicin is able to reduce the indomethacin-induced gastric 
microbleeding in human healthy subjects and the involvement of TRVP1, CGRP and SP in 
different gastrointestinal disorders show the importance of continuation of such studies to 
reach a better understanding of gastric mucosal defensive mechanisms in humans (Mózsik 
et al., 2005a). 
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Similar conclusions were obtained from the results of animal experiments and human 
observations, when we co-applied drugs acting on efferent and afferent vagal nerve fibres 
(Mózsik et al., 1997, 2009) and received combined actions. 
Recently, different molecular-pharmacological observations were carried out (and 
calculated, based on the dose-responses curves of drugs) with capsaicin, atropine, 
pirenzepine, cimetidine, ranitidine, famotidine, nizatidine, omeprazole, esomeprazole, PGI2, 
vitamin A, ǃ-carotene on the gastric basal acid output (BAO) in healthy human subjects 
(Mózsik et al., 2005), on changes of gastric transmucosal potential difference produced by 
ethanol (5 ml, 30 v/v% topically applied directly into the gastric mucosa by the way of 
endoscopic biopsy channel), on indomethacin-induced (3x25+25 mg orally) gastric 
microbleeding in healthy human subjects (Mózsik et al., 2007), and on gastric (basal and 
stimulated by betanechol, histamine and pentagastrin) acid secretion of pylorus-ligated rats 
(Mózsik et al., 2006) or on gastric mucosal damage produced by different chemicals 
(Indomethacin, HCl, ethanol, NaOH, concentrated NaCl solution) in rats (Mózsik et al., 
2006). 
The values of affinity (pD) and intrinsic activity (ǂ) curves of these compounds were 
calculated according to standard procedures employed in molecular-pharmacology (Csáky, 
1969). The values of the pD2 (dose necessary to inhibit the gastric acid secretion and gastric 
mucosal damage by 50%) and pA2 (dose necessary to produced 50% decrease in gastric acid 
secretion and in gastric mucosal damage) were calculated from the affinity and intrinsic 
activity curves. The intrinsic activity values obtained in relation to atropine (ǂ atropine = 1.00) 
were taken as standard values. 
The knowledge of affinity, intrinsic activity curves, values of pD2 and pA2 gives us an exact 
approach to understand the physiological and pharmacological roles of different 
compounds (Mózsik et al., 2006, 2007, 2009). 
The following pD2 values were obtained for the different drugs or substances inhibiting the 
gastric basal acid secretion (BAO): capsaicin, 5.88; atropine, 5.40; pirenzepine, 3.93; 
cimetidine, 2.23; ranitidine, 3.33; famotidine, 3.77; nizatidine, 3.23; omeprazole, 3.97 and 
esomeprazole,  3.97 (Mózsik et al., 2007). Similar results were obtained for these compounds 
inhibiting gastric mucosal damage produced by intragastric administration of ethanol or by 
orally applied indomethacin in healthy human subjects (Mózsik et al, 2005a). 
The results of these observations led us to conclude that the capsaicin-sensitive afferent 
nerves have the most important physiological regulation of gastric basal acid secretion 
(BAO) and of chemicals-induced gastric mucosal damage in human healthy subjects 
(Mózsik et al, 2005a, 2007, 2009). Similar results obtained in animals experiments for 
regulation of gastric acid secretion and of gastric mucosal damage (Mózsik et al, 2006). 
The unchanged functional state of capsaicin-sensitive afferentation, before and after classical 
eradication treatment in patients also offers to conclude an important regulatory function of 
gastric mucosa in patients with H. pylori chronic gastritis (in comparison the results 
obtained in patients with H. pylori positive gastritis vs. healthy persons) by TRVP1, CGRP 
and substance P during the eradication treatment. 
The most important message of this work (study) is that the gastric capsaicin-sensitive 
afferentation has a permanent defensive role(s) in the gastric mucosal defence. 
Consequently the modification in the function of capsaicin-sensitive afferent nerves offer 
new possibilities in human medical therapy. 
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